Ramipril in Chronic Kidney Disease

Primary Recommendation

The American College of Cardiology recommends starting ramipril (or another ACE inhibitor) at 2.5 mg once daily for CKD patients with hypertension and albuminuria, titrating to the maximum tolerated dose (typically 10 mg daily) to achieve a systolic blood pressure target of <120 mmHg 1, 2

The American College of Cardiology strongly recommends ramipril as first-line therapy for CKD with severely increased albuminuria (A3, ≥300 mg/g) without diabetes, demonstrating clear reductions in both kidney failure and cardiovascular events 1, 3, 4
The American Diabetes Association recommends ramipril for CKD with moderately-to-severely increased albuminuria (A2-A3, ≥30 mg/g) with diabetes, providing cardiovascular benefit and slowing progression to macroalbuminuria 3, 4, 5

The Kidney International journal recommends titrating ramipril to the highest approved dose tolerated (typically 10 mg daily for hypertension) to achieve maximum renoprotective benefit 2, 6

The Kidney International journal recommends checking serum creatinine and potassium within 2-4 weeks after initiating therapy or increasing dose 2, 7, 6
The American College of Cardiology recommends continuing ramipril if creatinine rises ≤30% within 4 weeks of initiation or dose increase, as this represents hemodynamic changes rather than true kidney damage 2, 7, 6

The American College of Cardiology recommends a primary target of systolic BP <120 mmHg using standardized office measurement, based on SPRINT trial evidence showing cardiovascular and mortality benefits that outweigh risks of hyperkalemia and acute kidney injury 1, 4, 8, 7
The American Heart Association recommends an alternative acceptable target of <130/80 mmHg per ACC/AHA guidelines 9, 10, 11, 7

The American College of Cardiology recommends that most CKD patients require combination therapy to achieve BP target <120 mmHg 1, 3, 4, 8
The Kidney International journal recommends using a long-acting dihydropyridine calcium channel blocker (e.g., amlodipine) as a second-line agent 7

The Kidney International journal recommends managing hyperkalemia with potassium-lowering measures rather than stopping ramipril, including dietary potassium restriction, loop diuretics, or potassium binders 2, 7

The Praxis Medical Insights journal recommends temporarily holding ramipril during illness with risk of volume depletion (vomiting, diarrhea), prior to procedures with contrast, or before major surgery 8, 6
The Kidney International journal recommends considering reducing dose or discontinuing ramipril to reduce uremic symptoms while treating kidney failure in advanced CKD (eGFR <15 mL/min/1.73 m²) 2

The Kidney International journal recommends not discontinuing ramipril for modest creatinine increases up to 30%, as this represents expected hemodynamic effects 2, 7
The American College of Cardiology recommends not using subtherapeutic doses—titrate to maximum tolerated dose for proven benefits 2, 6
The American College of Cardiology recommends not combining ramipril with other RAS blockers despite persistent proteinuria, as dual blockade increases harm 1, 3, 4, 2